Evaluation at ISMMS included comprehensive neurologic and neuropsychological assessment, a structural 3 T MRI scan, a clinical [18F]florbetapir PET scan to determine the presence or absence of amyloid, and a research PET scan using the novel [18F]T807/AV1451 tau ligand to determine the possible presence of tauopathy. Here, MAPT is linked to amyloidosis.